enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
Key Highlights
- ➤enVVeno to present investigational enVVe System at 38th annual TCT symposium
- ➤Rob Berman to deliver presentation during TCT’s Innovation in Endovascular Therapies session
- ➤enVVe targets severe deep venous insufficiency through transcatheter venous-valve replacement
- ➤Pivotal clinical study updates expected as enVVeno advances the enVVe System
Expert Statements
Rob Berman, Chief Executive Officer of enVVeno Medical
“We are excited to have this opportunity to bring the enVVe System to one of the most prominent global forums in cardiovascular medicine,”
Rob Berman, Chief Executive Officer of enVVeno Medical
“Deep venous insufficiency represents a significant unmet medical need, and we believe that enVVe has the potential to establish a new treatment paradigm for DVI.”
Rob Berman, Chief Executive Officer of enVVeno Medical
“We look forward to introducing enVVe to the global cardiovascular community as will continue to provide updates we advance the enVVe System through its pivotal clinical study.”
IRVINE, CA / ACCESS Newswire / November 2, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that it will present its investigational enVVe System® at the 38(th) annual Transcatheter Cardiovascular Conference (TCT(®)) (link) in San Diego, CA. The presentation, titled "Changing the Treatment Paradigm for Deep Venous Disease: Transcatheter Replacement Venous Valve," will be delivered by Rob Berman, Chief Executive Officer of enVVeno Medical, during the Innovation in Endovascular Therapies session on Monday, November 2, 2026 at 11:30 a.m. PT.
TCT is the world's premier scientific symposium dedicated to interventional cardiovascular medicine, bringing together more than 10,000 physicians, researchers, investors and healthcare leaders from around the globe. The presentation will introduce the enVVe System to a global audience of cardiovascular specialists and highlight the potential of a transcatheter approach to treating severe deep venous insufficiency.
Get started
Create a free account to read the full story.